Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector. CTL, J Exp Med, vol.184, p.485, 1996. ,
Classical chemotherapy for metastatic melanoma, Clin Exp Dermatol, vol.25, p.503, 2000. ,
The case for therapeutic vaccines, Melanoma. Res, vol.6, p.5, 1996. ,
Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial, Cancer, vol.68, p.1, 1991. ,
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study, J Clin Oncol, vol.13, p.1939, 1995. ,
Adoptive immunotherapy prevents prostate cancer in a transgenic animal model, Eur J Immunol, vol.29, p.1127, 1999. ,
Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol, vol.49, p.281, 1991. ,
Eradication of established tumors by CD8 + T cell adoptive immunotherapy, Immunity, vol.13, p.265, 2000. ,
High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy, J Immunother, vol.10, p.405, 1991. ,
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J Immunol, vol.154, p.3961, 1995. ,
Statistics notes: interactions 3: how to examine heterogeneity, Br Med J, vol.313, p.862, 1996. ,
5-S adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumourdraining lymph node cells, Immunology, vol.83, p.45, 1994. ,
Highscale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement, Cancer Immunol Immunother, vol.50, p.134, 2001. ,
URL : https://hal.archives-ouvertes.fr/inserm-02482159
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report, New Engl J Med, vol.319, p.1676, 1988. ,
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Natl Cancer Inst, vol.86, p.1159, 1994. ,
MHC antigens in human tumors, Immunol Lett, vol.29, p.181, 1991. ,
Some comments on frequently used multiple endpoint adjustment methods in clinical trials, Stat Med, vol.16, p.2529, 1997. ,
Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity, Immunology, vol.103, p.449, 2001. ,
Epidemiological aspects of cutaneous malignant melanoma, 1998. ,
, Oncol Rep, vol.5, p.905
Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma, Eur J Cancer, vol.32, p.735, 1996. ,
Progression-related expression of beta 3 integrin in melanomas and nevi, Hum Pathol, vol.30, p.562, 1999. ,
The design and analysis of sequential clinical trials, 1992. ,